Cambridge , UK , February 14, 2008: Executives from Senexis and O2H, both located in Cambridge , UK , announced an agreement under which O2H will provide synthetic and computational chemistry services to the drug discovery programmes at Senexis on an FTE basis.
"We believe our collaboration with O2H leverages the complementary expertise of both organisations and will benefit our search for new therapeutics to treat ageing-related diseases by helping Senexis increase the return on its chemistry research budget" said David Scopes, BSc, MSc, PhD - Chief Scientific Officer at Senexis.
Senexis, a recipient of recent Wellcome Trust funding, is a drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia, type II diabetes and dialysis related amyloidosis. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of these different diseases. Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Senexis is funded by BTG plc and the Wellcome Trust. Further information on Senexis can be found at www.senexis.com
O2H has its global HQ in the Science Park , Cambridge , UK , project offices in Boston and Tokyo , and a talented team of scientists in its world class discovery research centre in Ahmedabad , India . "Our scientific team in India with our project offices around the world helps our partners to maximise the value of their drug discovery programmes, from initial planning through to lead generation and lead optimisation thereby delivering enormous advantages to our growing portfolio of global clients," says Sunil Shah, CEO, O2H. Further information on O2H can be found at www.oxygenhealthcare.com
OXYGEN HEALTHCARE LTD
23 Cambridge Science Park
Babraham Research Campus
Babraham, Cambridge , UK